Treatment guidelines in psoriatic arthritis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32159790.
- Also identified by DOI 10.1093/rheumatology/kez383 and PMC identifier 7065461.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The treatment of PsA has changed substantially over the past 10 years. Clinical practice guidelines are developed to help busy clinicians rapidly integrate evolving knowledge of therapeutic management into practice. In this review, we compare PsA treatment recommendations or guidelines developed by one national organization [ACR and National Psoriasis Foundation (NPF) in 2018], one regional organization (EULAR in 2015), and one international organization (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis in 2015). We examine the development of guidelines in PsA more broadly and examine similarities and differences in the three sets of recommendations.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Psoriatic
- Biological Factors
- Molecular Targeted Therapy